Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein’s decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker’s Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. “I want to thank Glenn for his performance drive, strong business partnership, and exce ...

Stryker Corporation (SYK) is scheduled to release fourth-quarter 2024 results on Jan. 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 3.24%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $3.87 per share, indicating an increase of 11.9% year over year.The consensus mark for revenues is pinned at $6.35 billion, implying growth of 9.2% from the prior-year reported fig ...

Stryker Corporation (NYSE: SYK ) is a fantastic company with a long history of successfully commercializing innovative products in the medical device industry. Across its diversified business, it has shown steady growth in revenues, earnings, and FCF over multiple decades. ThisI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and ...

Analysts on Wall Street project that Stryker (SYK) will announce quarterly earnings of $3.87 per share in its forthcoming report, representing an increase of 11.9% year over year. Revenues are projected to reach $6.35 billion, increasing 9.2% from the same quarter last year.The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ove ...

Stryker Corporation (SYK) recently inked a definitive agreement to acquire all the issued and outstanding shares of common stock of Inari Medical, Inc. (NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.Through the acquisition of Inari Medical, Stryker is likely to expand its portfolio and provide life-saving solutions to patients with peripheral vascular diseases.Likely Trend of SYK Stock Following the NewsFollowing the announcement, shares of th ...

Key TakeawaysShares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share, valuing it at roughly $4.9 billion.The deal for the vascular medical device maker was first reported by Reuters Monday afternoon, sending Inari shares up 30% by the end of Monday trading. Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that ...

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous ...

Portage, Michigan, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2024 on Tuesday, January 28, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2024. Stryker will host a webcast at 4:30 p.m. ET on Tuesday, January 28, 2 ...

Stryker (SYK) is well-poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. An improvement in price also buoys optimism.Shares of this Zacks Rank #3 (Hold) company have risen 24.5% year to date compared with the industry’s 11.5% growth. The S&P 500 Index has increased 27.8% in the same time frame.Stryker, with a market capitalization of $142.8 billion, is one of the world’s largest medical device companies operating in the orthopedic market. ...

Company Overview - Stryker Corporation (SYK) has launched the Oculan Lighting Platform, an innovative surgical lighting solution aimed at enhancing surgical performance and patient safety by providing consistent, high-quality illumination [1][4][6] Product Features - The Oculan Lighting Platform offers bright, even light in challenging surgical environments, improving visualization and allowing surgeons to differentiate between various tissues and anatomical structures more effectively [1][4][6] - It incorporates advanced features such as Fly Eye technology for even light distribution, Auto Lux and Microspot features for uniform brightness, and SHD Mode to enhance contrast and reduce glare [6][7] - The platform is designed for durability and ease of use, allowing surgical teams to quickly adjust settings and integrate with existing Stryker surgical lights with minimal downtime [5][6] Market Performance - Following the announcement of the Oculan Lighting Platform, SYK shares closed flat at $388.68, with a year-to-date gain of 29.8%, outperforming the industry growth of 14.2% and the S&P 500's increase of 24% [2] - SYK currently has a market capitalization of $148.5 million and reported an earnings surprise of 3.2% in the last quarter [3] Industry Prospects - The global surgical lights market was valued at $1.85 billion in 2023 and is projected to grow at a CAGR of 5.9% from 2024 to 2030, driven by increasing regulatory approvals and a focus on improved patient care [8][9] - Factors such as rising product availability, high demand for well-equipped operating rooms, and improved accessibility to healthcare facilities, especially in emerging economies, are expected to further propel market growth [9]